{
    "root": "f4eb6157-0321-467a-a06b-69c2970eda71",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "lurasidone hydrochloride"
    },
    "value": "20250306",
    "ingredients": [
        {
            "name": "LURASIDONE HYDROCHLORIDE",
            "code": "O0P4I5851I"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "lurasidone hydrochloride indicated : • treatment adult adolescent patients ( 13 17 years ) schizophrenia [ ( 14.1 ) ] . • monotherapy treatment adult pediatric patients ( 10 17 years ) major depressive episode associated bipolar disorder ( indication ) [ ( 14.2 ) ] . • adjunctive treatment lithium valproate adult patients major depressive episode associated bipolar disorder ( indication ) [ ( 14.2 ) ] .",
    "contraindications": "lurasidone hydrochloride taken food ( least 350 calories ) . food substantially increases absorption lurasidone hydrochloride ( 2.3 , 12.3 ) . indication starting dose recommended dose schizophrenia – adults ( 2.1 ) 40 mg per day 40 mg 160 mg per day schizophrenia – adolescents ( 13 17 years ) ( 2.1 ) 40 mg per day 40 mg 80 mg per day indication– adults ( 2.2 ) 20 mg per day 20 mg 120 mg per day indication– pediatric patients ( 10 17 years ) ( 2.2 ) 20 mg per day 20 mg 80 mg per day • moderate severe renal impairment : recommended starting dose 20 mg per day , maximum recommended dose 80 mg per day ( 2.4 , 8.6 ) . • moderate severe hepatic impairment : recommended starting dose 20 mg per day . maximum recommended dose 80 mg per day moderate hepatic impairment 40 mg per day severe hepatic impairment ( 2.5 , 8.7 ) . • concomitant moderate cyp3a4 inhibitor ( e.g . , diltiazem ) : lurasidone hydrochloride dose reduced half original dose level . recommended starting dose 20 mg per day . maximum recommended dose 80 mg per day ( 2.6 , 7.1 ) . • concomitant moderate cyp3a4 inducer : may necessary increase dose lurasidone hydrochloride ( 2.6 , 7.1 ) .",
    "warningsAndPrecautions": "lurasidone hydrochloride tablets white off-white , round ( 20 mg 40 mg ) , white off-white , capsule ( 60 mg ) , light yellow , oval ( 80 mg ) white off-white , oval ( 120 mg ) identified strength-specific one-sided debossing , “ f3 ” ( 20 mg ) , “ f4 ” ( 40 mg ) , “ f5 ” ( 60 mg ) , “ f6 ” ( 80 mg ) “ f7 ” ( 120 mg ) . tablets supplied following strengths package configurations ( table 39 ) . table 39 : package configuration lurasidone hydrochloride tablets tablet strength package configuration ndc code 20 mg bottle 30 33342-419-07 bottle 90 33342-419-10 40 mg bottles 30 33342-420-07 bottles 90 33342-420-10 60 mg bottles 30 33342-421-07 bottles 90 33342-421-10 80 mg bottles 30 33342-422-07 bottles 90 33342-422-10 120 mg bottles 30 33342-423-07 bottles 90 33342-423-10 store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "• known hypersensitivity lurasidone hcl components formulation . angioedema observed lurasidone [ ( 6.1 ) ] . • strong cyp3a4 inhibitors ( e.g . , ketoconazole , clarithromycin , ritonavir , voriconazole , mibefradil , etc . ) [ ( 7.1 ) ] . • strong cyp3a4 inducers ( e.g . , rifampin , avasimibe , st. john ’ wort , phenytoin , carbamazepine , etc . ) [ ( 7.1 ) ] .",
    "indications_original": "Lurasidone hydrochloride is indicated for: \n                  • Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies (14.1)]. \n                      • Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (other indication) [see Clinical Studies (14.2)]. \n                      • Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (other indication) [see Clinical Studies (14.2)].",
    "contraindications_original": "Lurasidone hydrochloride should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone hydrochloride ( 2.3 , 12.3 ). Indication Starting Dose Recommended Dose Schizophrenia – adults ( 2.1 ) 40 mg per day 40 mg to 160 mg per day Schizophrenia – adolescents (13 to 17 years) ( 2.1 ) 40 mg per day 40 mg to 80 mg per day other indication– adults ( 2.2 ) 20 mg per day 20 mg to 120 mg per day other indication– pediatric patients (10 to 17 years) ( 2.2 ) 20 mg per day 20 mg to 80 mg per day • Moderate and Severe Renal Impairment: Recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day ( 2.4 , 8.6 ). • Moderate and Severe Hepatic Impairment: Recommended starting dose is 20 mg per day. The maximum recommended dose is 80 mg per day in moderate hepatic impairment and 40 mg per day in severe hepatic impairment ( 2.5 , 8.7 ). • Concomitant Use of a Moderate CYP3A4 inhibitor (e.g., diltiazem): Lurasidone hydrochloride dose should be reduced to half of the original dose level. Recommended starting dose is 20 mg per day. Maximum recommended dose is 80 mg per day ( 2.6 , 7.1 ). • Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of lurasidone hydrochloride ( 2.6 , 7.1 ).",
    "warningsAndPrecautions_original": "Lurasidone hydrochloride tablets are white to off-white, round (20 mg or 40 mg), white to off-white, capsule (60 mg), light yellow, oval (80 mg) or white to off-white, oval (120 mg) and identified with strength-specific one-sided debossing, “F3” (20 mg), “F4” (40 mg), “F5” (60 mg), “F6” (80 mg)  or “F7” (120 mg). Tablets are supplied in the following strengths and package configurations (Table 39).\n                  \n                     Table 39: Package Configuration for Lurasidone Hydrochloride Tablets\n                  \n                  \n                                                                                                              \n                  \n                     \n                        \n                        \n                        \n                     \n                     \n                        \n                            Tablet Strength \n                               \n                            Package Configuration \n                               \n                            NDC Code \n                               \n                        \n                        \n                            20 mg  \n                            Bottle of 30  \n                            33342-419-07 \n                        \n                        \n                            Bottle of 90  \n                            33342-419-10 \n                        \n                        \n                            40 mg  \n                            Bottles of 30  \n                            33342-420-07 \n                        \n                        \n                            Bottles of 90  \n                            33342-420-10 \n                        \n                        \n                            60 mg  \n                            Bottles of 30  \n                            33342-421-07 \n                        \n                        \n                            Bottles of 90  \n                            33342-421-10 \n                        \n                        \n                            80 mg  \n                            Bottles of 30  \n                            33342-422-07 \n                        \n                        \n                            Bottles of 90  \n                            33342-422-10 \n                        \n                        \n                            120 mg  \n                            Bottles of 30  \n                            33342-423-07 \n                        \n                        \n                            Bottles of 90  \n                            33342-423-10 \n                        \n                     \n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "• Known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.1)]. \n                      • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions (7.1)].\n                      • Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John’s wort, phenytoin, carbamazepine, etc.) [see Drug Interactions (7.1)]."
}